KIMMTRAK (tebentafusp-tebn)
TherapyBristol Myers Squibb
KIMMTRAK (tebentafusp-tebn) from Bristol Myers Squibb is an immune-engaging therapy used in HLA-A*02:01–positive uveal melanoma.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and KIMMTRAK. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where KIMMTRAK is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Uveal Melanoma Solid Tumor · Eye | HLA
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for KIMMTRAK.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering KIMMTRAK for eligible patients.
Test
SeCore CDx HLA Sequencing System
One Lambda, Inc. (ThermoFisher Scientific)
Method
SANGER
Specimen
Whole blood
1 approvalView test profile →